Sign In
Buy NMTR
$0.0722
+0 (+0%)
At Close: Nov 20, 2023
RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the U
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
07:30am, Thursday, 13'th May 2021
- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 follow
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit
07:30am, Wednesday, 21'st Apr 2021
RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will p
RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will
Why 9 Meters Biopharma Stock Is Soaring Today
01:39pm, Wednesday, 07'th Apr 2021
Some of the company's executives are making notable moves.
9 Meters Biopharma Stock Price Increased Over 10% Pre-Market: Why It Happened
05:09am, Wednesday, 07'th Apr 2021
The stock price of 9 Meters Biopharma Inc (NASDAQ: NMTR) increased by over 10% pre-market. This is why it happened.
9 Meters Biopharma Announces Closing of Offering of Common Stock
04:15pm, Monday, 05'th Apr 2021
RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its prev
NMTR Stock Price Fell Over 20% Pre-Market: Why It Happened
09:21am, Wednesday, 31'st Mar 2021
The stock price of 9 Meters Biopharma, Inc. (NASDAQ:NMTR) fell by over 20% pre-market. This is why it happened.
9 Meters Biopharma Prices Public Offering of Common Stock
10:30pm, Tuesday, 30'th Mar 2021
RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an unde
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020
04:00pm, Monday, 22'nd Mar 2021
FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure Announced po
9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update
07:30am, Monday, 15'th Mar 2021
Tuesday, March 23rd @ 11am Eastern Time RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today anno
9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences
07:30am, Wednesday, 10'th Mar 2021
- Oppenheimer 31st Annual Healthcare Conference - March 16th - 18th - Maxim Group 2021 Emerging Growth Virtual Conference - March 17th - 18th RALEIGH, NC / ACCESSWIRE / March 10, 2021 / 9 Meters Bioph
9 Meters Biopharma, Inc. Announces Chief Medical Officer's Presentation at NIH's Accelerating Progress in Celiac Disease Workshop
07:30am, Tuesday, 09'th Mar 2021
RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that chief medical officer Pa
9 Meters Biopharma (NMTR) is Overbought: Is A Drop Coming?
09:04am, Thursday, 04'th Feb 2021
9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Huge Upside Potential in 5 Stocks Trading Under $10
06:25am, Saturday, 30'th Jan 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
